BioSpace News Archive

AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today announced positive top-line data from a Phase 1 trial of ANB032, its investigational wholly owned anti-BTLA agonist antibody.

Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the first quarter ended March 31, 2022, and provided an update on its clinical pipeline and other corporate developments.

DURECT Corporation announced that it will report its first quarter 2022 financial results and host a conference call after the market close on Wednesday, May 4, 2022.

Sio Gene Therapies Inc. announced that it has provided the required notice to the University of Massachusetts to terminate its licensing agreement to develop and commercialize gene therapy product candidates, including AXO-AAV-GM1 and AXO-AAV-GM2, for the treatment of GM1 gangliosidosis and GM2 gangliosidosis, respectively.

ICON plc, a world-leading healthcare intelligence and clinical research organisation, reported its financial results for the first quarter ended March 31, 2022.

Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced, in conjunction with its Asia Pacific partner BeiGene, the acceptance of two abstracts for poster presentations at the upcoming 2022 ASCO Annual Meeting taking place virtually and in Chicago, IL from June 3 – 7, 2022.

Puma Biotechnology, Inc., a biopharmaceutical company, announced the release of titles of abstracts on neratinib to be presented at the 2022 American Society of Clinical Oncology Annual Meeting.

Oncocyte Corporation announced that it plans to present new data from ongoing clinical research evaluating the utility of DetermaIO™ at the upcoming American Society of Clinical Oncology Annual Meeting, taking place June 3-7, 2022 virtually and in-person in Chicago.

Mirati Therapeutics, Inc. (Nasdaq: MRTX), a clinical-stage targeted oncology company today announced the presentation of new clinical research showcasing the potential of its investigational KRASG12C inhibitor, adagrasib, in a study of patients with KRASG12C-mutated non-small cell lung cancer (NSCLC) at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.

Bausch Health Companies Inc. and its dermatology business, Ortho Dermatologics, announced the presentation of four poster presentations during the Florida Society of Dermatology Physician Assistants 2022 New Wave Dermatology Conference, which will take place in Coral Gables, Fla. from April 28 - May 1, 2022.